A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2012
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Aug 2011 New trial record